On November 29 and 30, the U.S. Food and Drug Administration (FDA), in collaboration with the Clinical Trials Transformation Initiative, hosted a public workshop on ways to increase the.
Coverage of sessions on disparities in access to clinical trials and cancer screening, as well as relationships each to outcomes. A joint session presented by ASCO and the European Society for Medical Oncology (ESMO) highlighted progress and lingering gaps in lung and colorectal screening.
While efforts are underway to improve access to cutting-edge oncology clinical trials for underserved patients, more work is needed to get the job done, said a panel of experts at the 2023 American Society of Clinical Oncology Annual Meeting.
FDA wants researchers conducting clinical trials to submit a plan on how they will diversify participant pools. While the effort to undo underrepresentation is appreciated, many say it s not enough.
New Recommendations to Eliminate Racial Bias in Blood Cancer Trials by Colleen Fleiss on February 18, 2021 at 11:12 PM
New recommendations are being designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites, said researchers from Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR).
Researchers from Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) are releasing recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.